Loading clinical trials...

Investigating the Effect of Vortioxetine in Adult ADHD Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT02327013•H. Lundbeck A/S

View on ClinicalTrials.gov

Summary

The purpose is to determine the effect of vortioxetine treatment on ADHD symptoms in adult patients with ADHD in a 12 weeks study.

Detailed Description

The study employed the Sequential Parallel Comparison Design (SPCD), a clinical study design which intend to increase signal detection by using two stages of treatment: * Stage 1 - first 6 weeks of the 12-weeks treatment period (Visit 2/Baseline 1 to Visit 5/Week 6) * Stage 2 - last 6 weeks of the 12-weeks treatment period (Visit 5/Baseline 2 to Visit 8/Week 12) In Stage 1, patients were randomized to placebo or vortioxetine 10 or 20mg. Patients on vortioxetine 10 or 20mg/day during Stage 1 remained on the same treatment in Stage 2. Responders to placebo in Stage 1 remained on Placebo in Stage 2. Patients who were placebo non-responders during Stage 1, defined as patients with a \<30% reduction in AISRS total score from Baseline 1, were re-randomized to placebo or vortioxetine 10 or 20mg/day in Stage 2.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The patient is willing and able to attend study appointments within the specified time windows.
•The patient is an outpatient.
•The patient is diagnosed with a primary diagnosis of ADHD according to the DSM-5™ classification.
•The patient has an AISRS total score ≥24.
•The patient has a CGI-S rating ≥4 (moderately ill or worse).

Exclusion Criteria

•The patient has previously been treated with vortioxetine.
•The patient has any current psychiatric disorder (DSM-IV-TR™ criteria), other than ADHD, as assessed using the Mini International Neuropsychiatric Interview (MINI).
•The patient has a known first-degree relative with bipolar disorder.
•The patient suffers from intellectual disability as evaluated by the Wechsler Abbreviated Scale of Intelligence (WASI) II vocabulary and matrix.
•The patient suffers from organic mental disorders, or mental disorders due to a general medical condition (DSM-5™ criteria).
•The patient has reported current use of, or has tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines \[including ecstasy\], barbiturates, benzodiazepines, and cannabinoids). If a patient tests positive for opiates due to incidental use of codeine containing medication, as assessed in a clinical interview, the drug screen may be repeated up to three weeks later but the retest result must be available from the central laboratory latest at Visit 2 and has to be negative for this patient to be eligible for enrolment. If a patient tests positive for amphetamines due to his/her ADHD current treatment, as confirmed by a clinical interview, the patient is eligible for enrolment provided this treatment is discontinued two weeks prior to the Baseline Visit.
•The patient has a history of two prior failed (\<50% improvement in symptoms) adequate trials of ADHD treatment.
•The patient has any other disorder for which the treatment takes priority over treatment of ADHD or is likely to interfere with study treatment or impair treatment compliance.
•The patient has a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect central nervous system functioning.
•The patient has attempted suicide within the last 6 months or is at significant risk of suicide (either in the opinion of the Investigator or defined as a "yes" to suicidal ideation questions 4 or 5 or answering "yes" to suicidal behaviour on the Columbia-Suicide Rating Scale (C-SSRS) within the last 12 months).

Locations (15)

US015

Beverly Hills, California, United States

US002

Garden Grove, California, United States

US004

National City, California, United States

US013

Bradenton, Florida, United States

US006

Gainesville, Florida, United States

US010

Alpharetta, Georgia, United States

US014

Libertyville, Illinois, United States

US011

Baltimore, Maryland, United States

US009

Boston, Massachusetts, United States

US016

Las Vegas, Nevada, United States

Key Dates

Start Date

December 1, 2014

Primary Completion Date

September 1, 2016

Completion Date

September 1, 2016

Last Updated

March 7, 2018

Enrollment

227

ACTUAL participants

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

vortioxetine 10 mg tablet

DRUG

vortioxetine 20 mg tablet

DRUG

Placebo tablet

OTHER

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

NCT07189442

Attention Deficit Hyperactivity Disorder (ADHD)Autism Spectrum Disorder (ASD)

View study

RECRUITINGNA

Virtual Reality in Rehabilitation of Executive Functions in Children With Attention Deficit Hyperactivity Disorder.

NCT06123741

Attention Deficit Hyperactivity Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Inclusion Criteria

Exclusion Criteria

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

Virtual Reality in Rehabilitation of Executive Functions in Children With Attention Deficit Hyperactivity Disorder.

Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure

A Dose-Response Study of the Cognitive and Physiological Effects of tDCS to the DLPFC

Effects of Probiotics on the Gut-brain Axis in Children

Characterization of Social Cognition Profiles in Children and Adolescents With Neurodevelopmental Disorders: a Clinical Study Using a Multidimensional Battery